Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus
Autore:
Molina, JM; Chene, G; Ferchal, F; Journot, V; Pellegrin, I; Sombardier, MN; Rancinan, C; Cotte, L; Madelaine, I; Debord, T; Decazes, JM;
Indirizzi:
Hop St Louis, Clin Maladies Infect, Dept Infect Dis, F-75475 Paris 10, France Hop St Louis Paris France 10 , Dept Infect Dis, F-75475 Paris 10, France Hop St Louis, Dept Pharm, F-75475 Paris, France Hop St Louis Paris France F-75475 uis, Dept Pharm, F-75475 Paris, France Hop St Louis, Virol Lab, F-75475 Paris 10, France Hop St Louis Paris France 10 Louis, Virol Lab, F-75475 Paris 10, France INSERM, U330, Dept Epidemiol Publ Hlth & Dev, Bordeaux, France INSERM Bordeaux France Dept Epidemiol Publ Hlth & Dev, Bordeaux, France Hop Pellegrin, Virol Lab, F-33076 Bordeaux, France Hop Pellegrin Bordeaux France F-33076 irol Lab, F-33076 Bordeaux, France Hotel Dieu, Dept Hepatol, Lyon, France Hotel Dieu Lyon FranceHotel Dieu, Dept Hepatol, Lyon, France Hop Begin, Dept Infect Dis, St Mande, France Hop Begin St Mande FranceHop Begin, Dept Infect Dis, St Mande, France
Titolo Testata:
JOURNAL OF INFECTIOUS DISEASES
fascicolo: 2, volume: 180, anno: 1999,
pagine: 351 - 358
SICI:
0022-1899(199908)180:2<351:TATARC>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
CD4 CELL COUNTS; ANTIRETROVIRAL THERAPY; HIV-INFECTION; CUBIC MILLIMETER; MONOTHERAPY; RECOMMENDATIONS; INDINAVIR; EFFICACY; ADULTS; SAFETY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Molina, JM Hop St Louis, Clin Maladies Infect, Dept Infect Dis, 1 Ave Claude Vellefaux, F-75475 Paris 10, France Hop St Louis 1 Ave Claude Vellefaux Paris France 10 10, France
Citazione:
J.M. Molina et al., "The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus", J INFEC DIS, 180(2), 1999, pp. 351-358

Abstract

A total of 151 previously untreated patients infected with human immunodeficiency virus type 1 (HIV-1) with CD4 cell counts greater than or equal to 200/mu L and plasma HIV-1 RNA levels of 10,000-100,000 copies/mL were randomly assigned to 24 weeks of open-labeled stavudine plus didanosine (group 1), zidovudine plus lamivudine (group 2), or stavudine plus didanosine followed by zidovudine plus lamivudine (group 3), The mean decrease in HIV-1 RNAlevel was greater in group 1 (2.26 log(10) copies/mL) than in groups 2 (1.26 log(10) copies/mL) or 3 (1.58 log(10) copies/mL; P < .0001). The mean increase in CD4 cell counts was greater in groups 1 (124 cells/mu L) and 3 (118 cells/mu L) than in group 2 (62 cells/mu L; P = .02). All regimens were generally well tolerated. The combination of stavudine plus didanosine reduced plasma HIV-1 RNA concentrations and increased CD4 cell counts more effectively than did the combination of zidovudine plus lamivudine or the regimen alternating both combinations.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 20:14:42